Australia's most trusted
source of pharma news
Monday, 02 March 2026
Posted 2 March 2026 AM
The Federal Government has claimed a world first for the multi-indication PBS listing of BMS immunotherapy drugs Opdivo and Yervoy from this month.
The landmark reimbursement is a major breakthrough in the way medicines are funded in Australia. It entrusts clinicians to use their clinical judgment to use the immunotherapy drugs in advanced or metastatic cancers based on the best available evidence.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.